LabGenomics USA Acquires Integrated Molecular Diagnostics (IMD) CLIA Labs

October 25, 2024

LabGenomics USA acquired Integrated Molecular Diagnostics (IMD) CLIA labs, expanding its U.S. footprint to four CLIA-certified laboratories and strengthening its molecular and oncology diagnostic capabilities. The deal broadens LabGenomics' geographic reach across the U.S. coasts and positions the company to launch new laboratory-developed tests (LDTs) and expand reimbursable services.

Buyers
LabGenomics USA
Targets
Integrated Molecular Diagnostics (IMD) CLIA labs
Location
California, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.